DRKS00030089
Recruiting
Not Applicable
Investigation of tumor evolution in sporadic and tumor disposition syndrome-associated tumors - CancerEvo
niversitätsklinikum Augsburg, Medizinische Fakultät, Universität Augsburg0 sites2,000 target enrollmentNovember 9, 2022
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- tumors in patients with a tumor predisposition syndromesporadic tumors
- Sponsor
- niversitätsklinikum Augsburg, Medizinische Fakultät, Universität Augsburg
- Enrollment
- 2000
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of one or more tumor diseases (in tumor predisposition or sporadic)
- •\- Treatment in the University Hospital Augsburg or in one of the partner hospitals
- •\- Availability of sufficient tumor material (paraffin material and/or fresh tissue) so that, according to the pathologist in charge, sufficient tumor material is still available for any future diagnostic tests
- •\- Written consent from the patient to participate in the study
Exclusion Criteria
- •\- Insufficient understanding of the German language
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Malignant transformation and tumour recurrence in sacrococcygeal teratoma, a congenital disorder in newbornsISRCTN17493302Foundation KiKa3,612
Recruiting
Not Applicable
Multiomics Tumor Evolution Model of NSCLCNon-small Cell Lung CancerNCT05352035Peking University People's Hospital300
Recruiting
Not Applicable
Retrospective study regarding tumor mutational burden (TMB) based on the Center for Cancer Genomics and Advanced Therapeutic (C-CAT) databaseSolid tumorsJPRN-UMIN000048347Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University11,984
Completed
Not Applicable
A retrospective study of malignant transformation of ovarian teratoma(KCOG-G1305s)Ovarian cancerJPRN-UMIN000011153Kansai clinical oncology group200
Active, not recruiting
Phase 1
The change in PET and MRI measurements over time as a predictor for metastatic colorectal cancer outcome.Advanced colorectal cancer, refractory to all available medicationsMedDRA version: 18.1Level: PTClassification code 10010035Term: Colorectal cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-006280-21-BEJules Bordet Institute53